UBS AM’s Crinetics Pharmaceuticals CRNX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $9.63M | Sell |
334,796
-12,785
| -4% | -$368K | ﹤0.01% | 1372 |
|
|
2025
Q1 | $11.7M | Buy |
347,581
+22,305
| +7% | +$748K | ﹤0.01% | 1158 |
|
|
2024
Q4 | $16.6M | Buy |
325,276
+53,529
| +20% | +$2.74M | ﹤0.01% | 1033 |
|
|
2024
Q3 | $13.9M | Buy |
271,747
+10,767
| +4% | +$550K | ﹤0.01% | 1098 |
|
|
2024
Q2 | $11.7M | Buy |
260,980
+49,160
| +23% | +$2.2M | ﹤0.01% | 1073 |
|
|
2024
Q1 | $9.92M | Buy |
211,820
+148,645
| +235% | +$6.96M | ﹤0.01% | 1000 |
|
|
2023
Q4 | $2.25M | Buy |
63,175
+349
| +0.6% | +$12.4K | ﹤0.01% | 1636 |
|
|
2023
Q3 | $1.87M | Buy |
62,826
+49,081
| +357% | +$1.46M | ﹤0.01% | 1664 |
|
|
2023
Q2 | $221K | Hold |
13,745
| – | – | ﹤0.01% | 2551 |
|
|
2023
Q1 | $221K | Sell |
13,745
-12,321
| -47% | -$198K | ﹤0.01% | 2551 |
|
|
2022
Q4 | $477K | Hold |
26,066
| – | – | ﹤0.01% | 2190 |
|
|
2022
Q3 | $512K | Buy |
26,066
+12,321
| +90% | +$242K | ﹤0.01% | 2337 |
|
|
2022
Q2 | $256K | Sell |
13,745
-1,276
| -8% | -$23.8K | ﹤0.01% | 2515 |
|
|
2022
Q1 | $330K | Sell |
15,021
-7,951
| -35% | -$175K | ﹤0.01% | 2570 |
|
|
2021
Q4 | $653K | Buy |
22,972
+6,832
| +42% | +$194K | ﹤0.01% | 2437 |
|
|
2021
Q3 | $340K | Hold |
16,140
| – | – | ﹤0.01% | 2596 |
|
|
2021
Q2 | $304K | Buy |
16,140
+1,637
| +11% | +$30.9K | ﹤0.01% | 2644 |
|
|
2021
Q1 | $222K | Hold |
14,503
| – | – | ﹤0.01% | 2546 |
|
|
2020
Q4 | $205K | Buy |
14,503
+4,000
| +38% | +$56.4K | ﹤0.01% | 2496 |
|
|
2020
Q3 | $165K | Sell |
10,503
-22,751
| -68% | -$357K | ﹤0.01% | 2424 |
|
|
2020
Q2 | $583K | Buy |
+33,254
| New | +$583K | ﹤0.01% | 2053 |
|